Business
Harrow launches initiative for expanded access, price cuts of branded products
The company is partnering with GoodRx to provide patients with discounts on select ophthalmic products.
Business
Harrow partners with Asembia for expanded branded ophthalmic product access
Partnership aims to simplify the prescribing process and ensure accessibility and affordability for patients; company also reports new Medicare coverage for VEVYE.
Products
Harrow relaunches Triesence to the US market
Returning after a +5-year shortage, the synthetic corticosteroid is indicated for managing severe ocular inflammatory conditions that don’t respond to topical treatments.
Products
Harrow's IHEEZO to be available via Apexus' 340 Prime Vendor Program
New contract through the federal government program also includes access to VIGAMOX and ILEVRO.
Research
Harrow reports 52-week data from phase 3 VEVYE extension study
FDA-approved cyclosporine solution to treat DED sustains statistically significant improvements in safety and efficacy, with continuous tear production improvements.
Products
Apotex to receive Canadian licensing rights for Harrow’s five branded ophthalmic products
Exclusive out-licensing agreement includes Verkazia, Cationorm PLUS, Zerviate, Vevye, and Iheezo.
Products
Harrow prepares to launch widespread market access for VEVYE
Company is partnering with three major healthcare tech platforms ahead of product launch next week.
Products
Harrow officially acquires TRIESENCE NDA
Company completes the final transfer of its ophthalmic product acquisitions from Novartis.
Products
Harrow transfers NDAs and launches 5 ophthalmic products
Pharmaceutical company continues its ophthalmic portfolio expansion.
Business
Harrow Health changes corporate name
Company cites recent ophthalmic product acquisitions in quest to focus exclusively on eye care.
Products
Harrow launches Vigamox in the US
Acquired from Novartis, the topical antibiotic eye drop is indicated to treat bacterial conjunctivitis caused by susceptible strains of organisms.
Products
Harrow buys North American commercial rights to Santen's ophthalmic brands
Acquisition includes six U.S. and two Canadian products; marks second deal for Harrow this week.
Products
Harrow purchases US, Canadian commercial rights to Novaliq's VEVYE
Newly-FDA-approved product is the first and only cyclosporine water- and preservative-free solution indicated for DED treatment.
Products
Harrow launches Iheezo for ocular surface anesthesia
Product is the first branded ocular aesthetic approved for the U.S. ophthalmic market in over a decade.
Products
Harrow launches three ophthalmic medicines in US
Company officially transfers NDAs for Ilevro, Nevanec, and Maxidex.
Products
Harrow launches next-gen atropine formulations
Patent-pending, compounded formulation is available in three concentrations.
Products
Harrow completes acquisition of exclusive US rights for 5 ophthalmic products
Deal is worth up to $175 million; includes an additional payout upon the commercial availability of Triesence later this year.
Products
Harrow announces in-office availability of Fortisite formulations
The addition of this on-demand therapeutic option for eyecare professionals across the U.S. could signal a change in standard of care within ophthalmic practices.
Business
Harrow to acquire US rights to 5 ophthalmic products from Novartis
Acquisition marks the second deal between the two companies in less than a year.
Business